Concord Drugs Ltd (538965) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 538965 | NSE: | Pharmaceuticals & Drugs | Small Cap

Concord Drugs Share Price

73 -1.16 -1.56%
as on 23-Jan'26 16:59

DeciZen - make an informed investing decision on Concord Drugs

Based on:

M-Cap below 100cr DeciZen not available

Concord Drugs stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
179.77
Market Cap:
96.2 Cr.
52-wk low:
26.1
52-wk high:
92.5

Is Concord Drugs Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Concord Drugs: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Concord Drugs Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 15.9%8.8%7.5%6.2%6.1%15.7%9.3%6%4.5%4.7%-
Value Creation
Index
0.1-0.4-0.5-0.6-0.60.1-0.3-0.6-0.7-0.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 50.757.551.848.151.351.45951.343.336.942
Sales YoY Gr.-13.4%-9.9%-7.2%6.8%0%14.8%-13%-15.7%-14.6%-
Adj EPS 2.50.20.40.50.40.71.810.40.30.4
YoY Gr.--91.1%86.4%26.8%-26.9%94.7%146%-47.3%-56.3%-28.6%-
BVPS (₹) 20.826.224.629.526.930.632.433.433.834.134.9
Adj Net
Profit
1.80.20.30.40.30.71.60.90.40.31
Cash Flow from Ops. 3.61.76.91.22.51.60.82.223.2-
Debt/CF from Ops. 5.59.128.23.9821.277.65.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -3.5%-6.4%-14.4%-14.6%
Adj EPS -20.9%-4.6%-45.2%-28.6%
BVPS5.7%4.9%1.7%0.9%
Share Price 4% 25.7% 32.6% 95.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
12.60.91.71.91.42.65.831.30.91.2
Op. Profit
Mgn %
16.49.68.87.66.56.39.58.58.510.29.9
Net Profit
Mgn %
3.50.30.60.90.61.32.71.710.81.3
Debt to
Equity
1.30.80.70.40.40.50.60.50.40.50
Working Cap
Days
263251474620416293241296348414181
Cash Conv.
Cycle
12810212914619921718921724228373

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Concord Drugs Ltd.

Standalone Consolidated
TTM EPS (₹) 0.4 0.4
TTM Sales (₹ Cr.) 42.2 45.1
BVPS (₹.) 34.9 34.9
Reserves (₹ Cr.) 33 33
P/BV 2.09 2.09
PE 179.77 166.97
From the Market
52 Week Low / High (₹) 26.10 / 92.52
All Time Low / High (₹) 11.68 / 92.52
Market Cap (₹ Cr.) 96.2
Equity (₹ Cr.) 13.2
Face Value (₹) 10
Industry PE 39.4

Management X-Ray of Concord Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Concord Drugs - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Concord Drugs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales50.6857.4951.8048.0851.3451.3658.9651.3143.2636.93
Operating Expenses 42.4451.9847.2444.4247.9948.1453.3646.9739.5833.17
Manufacturing Costs16.4410.3110.511017.2316.3515.6812.586.806.64
Material Costs23.8037.2334.0230.8926.6427.3927.0528.9927.0521.48
Employee Cost 1.612.571.732.293.273.474.143.553.873.31
Other Costs 0.581.880.981.240.850.936.501.851.871.74
Operating Profit 8.255.514.563.663.343.225.594.343.683.76
Operating Profit Margin (%) 16.3%9.6%8.8%7.6%6.5%6.3%9.5%8.5%8.5%10.2%
Other Income 0.200.150.370.090.120.090.100.010.010.01
Interest 2.572.421.881.591.541.421.681.621.591.72
Depreciation 2.912.582.401.711.461.371.761.601.541.42
Exceptional Items 000003.760000
Profit Before Tax 2.960.650.640.440.464.292.251.130.560.64
Tax 1.210.490.310.030.131.010.660.230.140.35
Profit After Tax 1.750.160.320.410.333.281.590.890.420.30
PAT Margin (%) 3.4%0.3%0.6%0.8%0.6%6.4%2.7%1.7%1.0%0.8%
Adjusted EPS (₹)2.40.20.40.50.43.81.81.00.40.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 15.0718.9919.3223.1623.4826.7728.3531.1433.8234.11
Share Capital 7.247.247.867.868.748.748.749.321010
Reserves 7.8211.7511.4615.2914.7418.0219.6121.8223.8224.11
Minority Interest0000000000
Debt19.9915.4412.419.839.5712.9715.6514.8014.0114.86
Long Term Debt12.216.183.410.690.883.751.701.020.031.31
Short Term Debt7.789.269.019.148.699.2213.9513.7813.9813.55
Trade Payables9.8216.3666.3742.649.023.157.185.153.213.41
Others Liabilities 7.624.738.317.1515.9475.275.555.266.20
Total Liabilities 52.4955.53106.4182.7758.0249.8856.4556.6356.3058.58

Fixed Assets

Gross Block27.4728.5230.7930.8430.9834.5836.4836.9737.2839.25
Accumulated Depreciation12.3014.8817.2818.9920.4621.3923.1524.7526.2927.71
Net Fixed Assets 15.1813.6413.5111.8510.5213.1913.3312.2210.9911.54
CWIP 0000.29100.550.921.632
Investments 00000001.421.621.62
Inventories8.1511.0318.6218.6416.4311.8717.4917.5018.5019.13
Trade Receivables25.4815.6571.1748.4325.4520.7322.8616.3513.9712.67
Cash Equivalents 0.040.230.060.180.040.060.060.100.170.22
Others Assets 3.6514.973.063.374.584.032.168.139.4311.42
Total Assets 52.4955.53106.4182.7758.0249.8856.4556.6356.3058.58

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 3.611.706.881.192.481.620.772.241.963.16
PBT 2.960.650.640.440.464.292.251.130.560.64
Adjustment 5.492.584.193.202.902.603.173.153.123.12
Changes in Working Capital -3.66-1.132.42-2.33-0.76-4.81-3.97-1.68-1.51-0.41
Tax Paid -1.17-0.39-0.38-0.12-0.12-0.47-0.67-0.35-0.20-0.19
Cash Flow From Investing Activity 0.23-1.04-2.21-0.34-0.84-3.67-2.44-2.27-1.21-2.32
Capex 0.23-1.04-2.28-0.35-0.85-3.67-2.46-0.86-1.02-2.33
Net Investments 000.0500.010.010.01-1.410.010.01
Others 000.020.010-000-0.200
Cash Flow From Financing Activity -3.86-3.94-4.80-0.73-1.792.071.680.05-0.69-0.87
Net Proceeds from Shares 002.9700.88001.890.680
Net Proceeds from Borrowing -0.4300-2.720.19-0.27-1.27-0.68-0.991.28
Interest Paid -2.57-2.36-1.71-1.49-1.45-1.25-1.41-1.56-1.59-1.72
Dividend Paid 0000000000
Others -0.85-1.58-6.053.48-1.413.594.360.401.21-0.43
Net Cash Flow -0.01-3.28-0.130.12-0.150.020.010.030.06-0.02

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)12.320.941.691.921.4113.065.7731.290.87
ROCE (%)15.98.847.496.176.0615.699.35.974.474.73
Asset Turnover Ratio0.951.060.640.510.730.951.110.910.770.64
PAT to CFO Conversion(x)2.0610.6321.52.97.520.490.482.524.6710.53
Working Capital Days
Receivable Days190131306454263164135139128132
Inventory Days506110414112510191124152186
Payable Days2111284446443548170785656

Concord Drugs Ltd Stock News

Concord Drugs Ltd FAQs

The current trading price of Concord Drugs on 23-Jan-2026 16:59 is ₹73.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Jan-2026 the market cap of Concord Drugs stood at ₹96.18.
The latest P/E ratio of Concord Drugs as of 22-Jan-2026 is 179.8.
The latest P/B ratio of Concord Drugs as of 22-Jan-2026 is 2.09.
The 52-week high of Concord Drugs is ₹92.52 and the 52-week low is ₹26.10.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Concord Drugs is ₹42.20 ( Cr.) .

About Concord Drugs Ltd

No data to display
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×